Dapiglutide
Sources
registry, as of 2024-12-05Stale
https://clinicaltrials.gov/study/NCT05788601
Dapiglutide for the Treatment of Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor University Hospital, Gentofte, Copenhagen. Enrollment 54. Conditions Obesity; Inflammation. This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered subcutaneously once weekly
ClinicalTrials.gov NCT05788601 protocol and results modules
registry, as of 2025-05-06Stale
https://clinicaltrials.gov/study/NCT06758583
A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide. Overall status COMPLETED. Phases PHASE1. Lead sponsor Zealand Pharma. Enrollment 30. Conditions Overweight and Obesity. This is a phase 1, open-label, single-center, randomized, parallel-group trial designed to investigate the pharmacokinetic profiles, safety, and tolerability of a single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and
ClinicalTrials.gov NCT06758583 protocol and results modules